Liver/Biliary Disorders News

WASHINGTON — Patient survival was no different for living donor liver transplant recipients with a MELD score greater than 25 compared with those with lower MELD scores, according to data presented at The Liver Meeting.

WASHINGTON D.C. — In a Healio video exclusive, Ron Cooper, CEO of Albireo Pharma, highlighted positive top-line safety and efficacy results of Bylvay for the treatment of Alagille syndrome in patients from birth to early adulthood.

WASHINGTON — The MELD score at transplant minus three points policy led to poor survival and recurrence outcomes after liver transplantation among patients with hepatocellular carcinoma, according to research at The Liver Meeting.

WASHINGTON — Age-standardized mortality rates for alcohol-associated liver disease and nonalcoholic fatty liver disease increased the most among the young and non-Hispanic whites, Blacks and Native Americans during the COVID-19 pandemic.

WASHINGTON — Magnetic resonance elastography was among the most accurate screening test to identify patients with at-risk nonalcoholic steatohepatitis, according to study results presented at The Liver Meeting.

WASHINGTON — Funding research into liver disease, and reducing inequities in liver care, requires investment proportionate to its prevalence and burden on the health care system, said a keynote speaker at The Liver Meeting.

WASHINGTON — The Multi-Organ Dysfunction and Evaluation for Liver transplantation, or MODEL, score predicted high probability of mortality in transplant patients with severe acute-on-chronic liver failure, according to research.

WASHINGTON — MELD 3.0 more accurately predicted the risk for 90-day waitlist mortality compared with MELD-Na among adolescent patients on a liver transplant waitlist, according to research presented at The Liver Meeting.

WASHINGTON — Adding weight management care into a multidisciplinary nonalcoholic fatty liver disease program improved referrals for bariatric surgery at a rate of 25 times higher than the national average, according to Yale study results.

WASHINGTON — Black and Latino patients are underrepresented in cirrhosis clinical trials, underpinning the need for systematic improvement, according to research presented at The Liver Meeting.